Korsana Biosciences (KRSA) vs Ocular Therapeutix (OCUL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Korsana Biosciences (KRSA) has outperformed Ocular Therapeutix (OCUL) over the past year, gaining 90.0% versus a loss of 37.2%. Over five years, OCUL leads with a -35.4% price change compared with -91.1% for KRSA. Ocular Therapeutix is the larger company by market cap ($1.65 billion vs $1.53 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KRSA | OCUL |
|---|---|---|
| Share price | $33.51 | $7.51 |
| Market cap | $1.53B | $1.65B |
| 1-day change | +6.37% | +3.87% |
| YTD return | +276.94% | -40.44% |
| 1-year return | +89.97% | -37.24% |
| 5-year return | -91.10% | -35.39% |
| EPS (TTM) | $-7.07 | $-1.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $59.36 | $16.44 |
| 52-week low | $7.19 | $6.23 |
| Distance from 52-week high | -43.55% | -54.32% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +31.30% | +260.72% |
| Average volume | 32.06K | 2.80M |
| Shares outstanding | 45.54M | 219.62M |
| Employees | 19 | 325 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KRSA has outperformed OCUL by 127.2 percentage points over the past year.
About Korsana Biosciences
KRSA stock →Korsana Biosciences, Inc. develops therapeutic antibodies for the treatment of neurodegenerative diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees
About Ocular Therapeutix
OCUL stock →Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 325 employees
KRSA vs OCUL FAQ
Which is bigger, Korsana Biosciences or Ocular Therapeutix?
Ocular Therapeutix (OCUL) is larger, with a market capitalization of $1.65B compared with $1.53B for Korsana Biosciences (KRSA).
Which stock has performed better over the past year, KRSA or OCUL?
KRSA returned +89.97% over the past 12 months, compared with -37.24% for OCUL (price return, excluding dividends). Past performance does not predict future results.
Are Korsana Biosciences and Ocular Therapeutix in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.